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tiating cells with stem/progenitor cell features. Yamashita T, Ji J,
Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX,
Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY,
Wang XW. Abstract reprinted from Gastroenterology 2009;136
(3):1012–1024 with permission from Elsevier.
Abstract: Background & Aims: Cancer progression/metasta-
ses and embryonic development share many properties includ-
ing cellular plasticity, dynamic cell motility, and integral
interaction with the microenvironment. We hypothesized that
the heterogeneous nature of hepatocellular carcinoma (HCC),
in part, may be owing to the presence of hepatic cancer cells
with stem/progenitor features. Methods: Gene expression proﬁl-
ing and immunohistochemistry analyses were used to analyze
235 tumor specimens derived from 2 recently identiﬁed HCC
subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and
EpCAM(-) AFP(-) HCC). These subtypes differed in their expres-
sion of AFP, a molecule produced in the developing embryo,
and EpCAM, a cell surface hepatic stem cell marker. Fluores-
cence-activated cell sorting was used to isolate EpCAM(+) HCC
cells, which were tested for hepatic stem/progenitor cell proper-
ties. Results: Gene expression and pathway analyses revealed
that the EpCAM(+) AFP(+) HCC subtype had features of hepatic
stem/progenitor cells. Indeed, the ﬂuorescence-activated cell
sorting-isolated EpCAM(+) HCC cells displayed hepatic cancer
stem cell-like traits including the abilities to self-renew and dif-
ferentiate. Moreover, these cells were capable of initiating
highly invasive HCC in nonobese diabetic, severe combined
immunodeﬁcient mice. Activation of Wnt/beta-catenin signal-
ing enriched the EpCAM(+) cell population, whereas RNA inter-
ference-based blockage of EpCAM, a Wnt/beta-catenin signaling
target, attenuated the activities of these cells. Conclusions:
Taken together, our results suggest that HCC growth and inva-
siveness is dictated by a subset of EpCAM(+) cells, opening a new
avenue for HCC cancer cell eradication by targeting Wnt/beta-
catenin signaling components such as EpCAM.
 2009 European Association for the Study of the Liver. Pub-
lished by Elsevier B.V.
The concept of cancer stem cells (CSCs) or tumour initiating cells
(TICs) has been well established in several hematologic cancers,
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tains cancer tissues by sustaining phenotypically diverse cancer
cells. These cells are able to self-renew and generate progeny
cells, leading to cellular heterogeneity of the tumour. CSCs have
a high level of resistance to chemotherapy and radiotherapy. A
few of these cells may survive and lead to relapse of the disease
(see [1] for review). This model may thus explain the extensive
heterogeneity, high rates of recurrence in mortality, and the high
level of resistance to conventional anticancer therapy observed in
hepatocellular carcinoma (HCC) [2].
Yamashita et al. recently published an article addressing this
issue [3]. They found a population of HCC cells expressing
EpCAM, an epithelial cell adhesion molecule previously identiﬁed
as a marker for stem/progenitor cells of adult liver and oval cells
[4,5]. These cells seemed to present all the characteristics of CSCs.
In a previous study, these authors identiﬁed new prognostic sub-
types of HCCs by gene proﬁling. HCCs with the poorest prognosis
were EpCAM+ AFP+ (a-foetoprotein) and showed hepatic cancer
cell-like traits, whereas EpCAM AFP HCCs had a more favour-
able outcome and displayed features of mature hepatocytes [6].
In the present study, the authors analyzed the EpCAM signature
in more than 150 tumour samples, and conﬁrmed that EpCAM+
AFP+ HCCs had a signiﬁcantly shorter survival, with a higher fre-
quency of portal vein invasion, than EpCAM AFP HCCs. They
also observed that EpCAM expression was concentrated at the
invasive border of the tumour and thus may be a marker of cells
with CSC properties. FACS analysis of hepatoma cell lines was
used to separate two distinct populations of hepatoma cells on
the basis of EpCAM expression levels. The authors showed that
cells with high level of EpCAM (EpCAM+) but not EpCAM cells
(with low level of EpCAM) expressed markers of hepatic stem
cells, formed colonies in soft agar and efﬁciently formed non-
adherent spheroid structures and were more invasive than the
EpCAM cells. When xenografted in NOD-SCID mice, only
EpCAM+ cells could efﬁciently initiate the development of inva-
sive tumours, even after serial transplantation, demonstrating
that EpCAM+ cells display CSC-like characteristics. EpCAM cells
did not show these properties. These data are strongly supported
by the analysis of NOD-SCID mice after transplantation of
EpCAM+ and EpCAM HCC cells isolated from two fresh surgical
specimens from patients with high serum AFP levels. Only
EpCAM+ cells were able to induce tumours in NOD-SCID mice.10 vol. 52 j 280–281
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The gene encoding EpCAM is a target of the Wnt/b-catenin
pathway [7], and this signalling pathway controls the prolifer-
ation of hepatic stem cells [8]. The authors thus showed that
activation of b-catenin signalling by pharmacological
approaches could increase the amount of spheroids formed
by HuH7 cells. By contrast, inhibition by siRNA of either b-
catenin or EpCAM led to a strong reduction in the capacity of
cells to initiate tumours. These results show that EpCAM may
serve as a marker for HCC CSC cells, and may be a potential
new therapeutic target for HCC.
The work of Yamashita et al. highlights the link between
EpCAM and the Wnt/b-catenin signalling pathway, but, as yet,
whether b-catenin-activated HCC follows the CSC model remains
unclear. Two different possible modes of activation of b-catenin
signalling in human HCCs may be considered. The ﬁrst mode of
activation is the better characterized one, it results from activat-
ing mutations of the b-catenin gene that confer speciﬁc charac-
teristics to HCCs, both in terms of their morphology and their
expression pattern proﬁles [9,10]. In particular, b-catenin-
mutated HCCs are usually largely homogeneous tumours with a
well-differentiated pattern [9] and thus do not appear to ﬁt with
the CSC model. The second mode of b-catenin activation is not
linked to any mutational events within the Wnt/b-catenin
pathway, but results from cross-talk with other carcinogenic
pathways (HGF, TGFb and probably others), which stabilize
b-catenin, and is likely to be involved in epithelial-to-mesenchy-
mal transition during tumour invasion and metastasis [11,12].
Given the different levels of b-catenin activation in each of these
two scenarios, the differences in the Wnt proﬁle in these two
types of HCC is not surprising. The EpCAM+ signature described
by Yamashita et al. is probably mainly associated with the second
of these scenarios. This would explain the poorer prognosis
observed for EpCAM+ HCCs; b-catenin activation in this subtype
of HCCs may promote both the hepatic stem/progenitor traits
of these tumours and their invasiveness through EMT.
The identiﬁcation of a subclass of EpCAM+ HCC that displays
CSC characteristics has important clinical consequences as these
cells may be preferential therapeutic targets. It will also be
important to determine whether the CSC model also applies to
other subclass of HCCs. Indeed, a deeper understanding of the cel-
lular organization in HCC is needed. However, this remains a dif-
ﬁcult challenge due to the relatively poor efﬁciency of graftingJournal of Hepatology 201HCC cells isolated from surgical specimens into immuno-deﬁ-
cient mice.Acknowledgements
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